vs
Antero Midstream Corp（AM）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
Antero Midstream Corp的季度营收约是REPLIGEN CORP的1.5倍（$291.1M vs $197.9M），Antero Midstream Corp净利率更高（41.5% vs 6.7%，领先34.8%），REPLIGEN CORP同比增速更快（13.6% vs -7.3%），Antero Midstream Corp自由现金流更多（$186.9M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 3.9%）
Antero Midstream Corp是美国能源企业，注册地为特拉华州，总部设于科罗拉多州丹佛市。公司全部油气储量均位于阿巴拉契亚盆地，采用水力压裂技术开采，核心业务涵盖油气勘探开发相关领域。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
AM vs RGEN — 直观对比
营收规模更大
AM
是对方的1.5倍
$197.9M
营收增速更快
RGEN
高出21.0%
-7.3%
净利率更高
AM
高出34.8%
6.7%
自由现金流更多
AM
多$169.3M
$17.6M
两年增速更快
RGEN
近两年复合增速
3.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $291.1M | $197.9M |
| 净利润 | $120.7M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | 60.9% | 9.0% |
| 净利率 | 41.5% | 6.7% |
| 营收同比 | -7.3% | 13.6% |
| 净利润同比 | 2.1% | 143.9% |
| 每股收益（稀释后） | $0.25 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRGEN
| Q1 26 | $291.1M | — | ||
| Q4 25 | $297.0M | $197.9M | ||
| Q3 25 | $294.8M | $188.8M | ||
| Q2 25 | $305.5M | $182.4M | ||
| Q1 25 | $291.1M | $169.2M | ||
| Q4 24 | $287.5M | $174.1M | ||
| Q3 24 | $269.9M | $154.9M | ||
| Q2 24 | $269.8M | $154.1M |
净利润AMRGEN
| Q1 26 | $120.7M | — | ||
| Q4 25 | $51.9M | $13.3M | ||
| Q3 25 | $116.0M | $14.9M | ||
| Q2 25 | $124.5M | $14.9M | ||
| Q1 25 | $120.7M | $5.8M | ||
| Q4 24 | $111.2M | $-30.3M | ||
| Q3 24 | $99.7M | $-654.0K | ||
| Q2 24 | $86.0M | $3.3M |
毛利率AMRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% |
营业利润率AMRGEN
| Q1 26 | 60.9% | — | ||
| Q4 25 | 33.8% | 9.0% | ||
| Q3 25 | 61.2% | 8.9% | ||
| Q2 25 | 61.0% | 7.6% | ||
| Q1 25 | 60.9% | 3.9% | ||
| Q4 24 | 61.8% | -17.7% | ||
| Q3 24 | 60.2% | -5.1% | ||
| Q2 24 | 56.6% | 1.0% |
净利率AMRGEN
| Q1 26 | 41.5% | — | ||
| Q4 25 | 17.5% | 6.7% | ||
| Q3 25 | 39.3% | 7.9% | ||
| Q2 25 | 40.8% | 8.2% | ||
| Q1 25 | 41.5% | 3.4% | ||
| Q4 24 | 38.7% | -17.4% | ||
| Q3 24 | 37.0% | -0.4% | ||
| Q2 24 | 31.9% | 2.2% |
每股收益（稀释后）AMRGEN
| Q1 26 | $0.25 | — | ||
| Q4 25 | $0.11 | $0.24 | ||
| Q3 25 | $0.24 | $0.26 | ||
| Q2 25 | $0.26 | $0.26 | ||
| Q1 25 | $0.25 | $0.10 | ||
| Q4 24 | $0.23 | $-0.55 | ||
| Q3 24 | $0.21 | $-0.01 | ||
| Q2 24 | $0.18 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.4M | $767.6M |
| 总债务越低越好 | $3.2B | $542.2M |
| 股东权益账面价值 | $2.0B | $2.1B |
| 总资产 | $5.9B | $2.9B |
| 负债/权益比越低杠杆越低 | 1.63× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资AMRGEN
| Q1 26 | $180.4M | — | ||
| Q4 25 | $180.4M | $767.6M | ||
| Q3 25 | — | $748.7M | ||
| Q2 25 | — | $708.9M | ||
| Q1 25 | — | $697.2M | ||
| Q4 24 | — | $757.4M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $809.1M |
总债务AMRGEN
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $542.2M | ||
| Q3 25 | $3.0B | $537.9M | ||
| Q2 25 | $3.0B | — | ||
| Q1 25 | $3.1B | — | ||
| Q4 24 | $3.1B | $525.6M | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $3.2B | — |
股东权益AMRGEN
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | $2.1B | ||
| Q3 25 | $2.1B | $2.1B | ||
| Q2 25 | $2.1B | $2.1B | ||
| Q1 25 | $2.1B | $2.0B | ||
| Q4 24 | $2.1B | $2.0B | ||
| Q3 24 | $2.1B | $2.0B | ||
| Q2 24 | $2.1B | $2.0B |
总资产AMRGEN
| Q1 26 | $5.9B | — | ||
| Q4 25 | $5.9B | $2.9B | ||
| Q3 25 | $5.7B | $2.9B | ||
| Q2 25 | $5.7B | $2.9B | ||
| Q1 25 | $5.8B | $2.9B | ||
| Q4 24 | $5.8B | $2.8B | ||
| Q3 24 | $5.8B | $2.8B | ||
| Q2 24 | $5.8B | $2.9B |
负债/权益比AMRGEN
| Q1 26 | 1.63× | — | ||
| Q4 25 | 1.63× | 0.26× | ||
| Q3 25 | 1.46× | 0.26× | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | 1.47× | 0.27× | ||
| Q3 24 | 1.49× | — | ||
| Q2 24 | 1.50× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $198.9M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $186.9M | $17.6M |
| 自由现金流率自由现金流/营收 | 64.2% | 8.9% |
| 资本支出强度资本支出/营收 | 11.1% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.65× | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流AMRGEN
| Q1 26 | $198.9M | — | ||
| Q4 25 | $255.5M | $25.7M | ||
| Q3 25 | $212.8M | $48.1M | ||
| Q2 25 | $265.2M | $28.6M | ||
| Q1 25 | $198.9M | $15.0M | ||
| Q4 24 | $232.7M | $39.2M | ||
| Q3 24 | $184.9M | $49.3M | ||
| Q2 24 | $215.8M | $42.2M |
自由现金流AMRGEN
| Q1 26 | $186.9M | — | ||
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $43.4M | ||
| Q2 25 | — | $21.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $33.6M | ||
| Q3 24 | $184.3M | $42.3M | ||
| Q2 24 | $147.2M | $37.4M |
自由现金流率AMRGEN
| Q1 26 | 64.2% | — | ||
| Q4 25 | — | 8.9% | ||
| Q3 25 | — | 23.0% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | 68.3% | 27.3% | ||
| Q2 24 | 54.6% | 24.3% |
资本支出强度AMRGEN
| Q1 26 | 11.1% | — | ||
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | 0.0% | 3.2% | ||
| Q3 24 | 0.2% | 4.5% | ||
| Q2 24 | 25.4% | 3.1% |
现金转化率AMRGEN
| Q1 26 | 1.65× | — | ||
| Q4 25 | 4.92× | 1.93× | ||
| Q3 25 | 1.84× | 3.23× | ||
| Q2 25 | 2.13× | 1.92× | ||
| Q1 25 | 1.65× | 2.57× | ||
| Q4 24 | 2.09× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 2.51× | 12.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AM
| Gathering and compression–Antero Resources | $238.0M | 82% |
| Other | $52.3M | 18% |
| Water handling–third party | $505.0K | 0% |
| Gathering and compression–third party | $295.0K | 0% |
RGEN
暂无分部数据
